23 April 2021 - The latest dustup over the cost of cystic fibrosis medicines sold by Vertex Pharmaceuticals is taking place in Australia, where an independent committee recommended that the government not cover a new combination treatment due to the cost and financial implications.
In explaining its decision, the PBAC acknowledged that the medicine, called Trikafta, provided a significant benefit for some patients, especially those with a particular gene mutation.